This article is more than 5 years old. Information may no longer be current.

Myoscience to be acquired by Pacira Pharmaceuticals for $220 million

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Myoscience announced it has entered into a definitive agreement to be acquired by Pacira Pharmaceuticals Inc., according to a company press release.

Pacira will reportedly acquire Myoscience for up to $220 million under the agreement terms. This includes $120 million in cash up front and $100 million after commercial and regulatory milestones are achieved. The transaction is expected to close by early April 2019.

“This agreement represents an exciting accomplishment for the Myoscience team, and is good news for patients and physicians,” Timothy I. Still, president and CEO of Myoscience, said in the release. “We are confident that Pacira is the ideal organization to bring this technology to more physicians and their patients in need of effective non-opioid pain relief.”

Reference:

www.myoscience.com